Want to join the conversation?
$AMGN said the safety profile of erenumab was similar to placebo across both treatment arms. There was no adverse event reported in greater than 5% of patients treated with erenumab. The most common adverse events were injection site pain, upper respiratory tract infection and nausea.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th